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Abstract
The emergence of carbapenem resistance in Pseudomonas aeru-
ginosa threatens the efficacy of this important anti-pseudomonal
antibiotic class. Between 2003 and 2006, an increase in the
number of carbapenem-resistant P. aeruginosa isolates at the
Zonguldak Karaelmas University Hospital was observed (Zongul-
dak, Turkey). To assess the imipenem resistance mechanisms
emerging in these P. aeruginosa isolates, they were characterized
by amplified fragment length polymorphism typing, which
revealed diversity among imipenem-resistant isolates as well as
two clonally related outbreak groups. The molecular mechanism
of carbapenem resistance was characterized in a representative
isolate from each clonal group. Mutational disruption of oprD
was the most frequently encountered resistance mechanism
(23/27 isolates).
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Pseudomonas aeruginosa is a major cause of nosocomial infec-
tions and is associated with hospital-acquired pneumonia as
well as urinary tract, surgical site and bloodstream infections
[1,2]. These infections are difficult to control with antibiotics
and disinfectants because of the high intrinsic resistance of
this organism. The use of broad-spectrum antimicrobial
agents such as the carbapenem antibiotics is recommended
for suspected P. aeruginosa infections as they have excellent
activity against this species [3,4]. However, resistance to
carbapenem antibiotics such as imipenem has risen among
P. aeruginosa and can also emerge during therapy causing
treatment failure [5]. This study characterizes the mecha-
nisms contributing to imipenem resistance in P. aeruginosa
clinical isolates from Turkey, a region where carbapenem
resistance rates are high [6,7].
Seventy-four P. aeruginosa isolates exhibiting imipenem
resistance were identified at Zonguldak Karaelmas University
Hospital between 2003 and 2006 with increasing prevalence
in their isolation over the study interval (5, 6, 19 and 43 iso-
lates per year). Antibiotic susceptibilities testing showed that
amikacin was the most effective antimicrobial against all the
isolates (81%) in vitro, followed by cefepime (64%) and piper-
acillin–tazobactam (63%).
To assess whether the increased isolation rate of carbape-
nem-resistant P. aeruginosa isolates was caused by a clonal
outbreak, strain typing by amplified fragment length polymor-
phism (AFLP) was performed [8]. The AFLP fingerprinting
showed that the 74 imipenem-resistant strains belonged to
27 divergent clonal lineages indicating strain diversity. How-
ever, two larger clonal groups were identified (n20 and n10),
which contributed to the increase in numbers in 2005 and
2006. The first cluster of isolates (n20) appeared in April
2005 and the second group (n11) first appeared in January
2006, followed by an increase in the numbers isolated. Iso-
lates from both clusters were no longer detected after Sep-
tember 2006. Despite the two clonal transmission episodes,
emergence of imipenem resistance occurred in independent
strains. A single representative strain from each of the 27
AFLP clonal groups was chosen for further investigation into
the mechanisms of imipenem resistance in the diverse
P. aeruginosa clinical strains isolated.
As imipenem resistance could be explained by the dissemi-
nation of a transferrable resistance mobile element among
different strains, a representative isolate from each AFLP clo-
nal group was screened for the presence of diverse carbape-
nem resistance genes, including blaOXA-23, blaOXA-24, blaOXA-51,
blaOXA-58, blaGIM-1, blaSIM-1, blaSPM-1, blaIMP, and blaVIM as previ-
ously described using isolated bacterial DNA as a template
[9]. No previously characterized carbapenemase resistance
genes were identified, suggesting that the imipenem
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resistance observed is not the result of these transferrable
resistance genes. In addition, all isolates were negative for
metallo-b-lactamase production according to the Etest MBL
strip assay. The transfer of carbapenem resistance from
resistant isolates to a susceptible recipient strain by conjuga-
tion could not be demonstrated (data not shown), suggesting
that imipenem resistance in these strains is unlikely to be
transferrable and consequently may be the result of chromo-
somal resistance mechanisms.
As almost all (73 out of 74) imipenem-resistant strains
also exhibited chloramphenicol resistance, we hypothesized
that the LysR-type transcriptional regulator, MexT, might be
involved in this phenotype. MexT directly regulates the Mex-
EF-oprN efflux system that confers resistance to a number
of antibiotics including chloramphenicol [10,11]. In addition,
MexT has also been shown to play a role in the down-regu-
lation of the outer membrane porin, OprD, which facilitates
uptake of imipenem into the cell [12]. As determined by
quantitative RT-PCR, the ratio of detected mexE transcript
relative to that of proC (internal control) in PA14nfxC (mex-
EF-oprN over-expressing control) was 262 ± 73-fold higher
than the ratio detected in PA14 wild-type cells (Tables 1 and
2). In contrast, none of the isolates exhibited a mexE : proC
expression ratio that was significantly higher than that of
PA14 wild-type, confirming that mexE is not induced in these
strains. This suggests that MexT is not constitutively active in
these strains and that imipenem and chloramphenicol
resistance occurred independent of the MexT regulatory
pathway.
Mutational inactivation of oprD is known to occur in
P. aeruginosa clinical isolates leading to carbapenem resistance
[1]. To establish whether this could have occurred in the 27
representative imipenem-resistant isolates from this study,
the oprD gene was sequenced in each isolate. This revealed
that the oprD sequence was modified in about 85% of the
imipenem-resistant isolates. The mutations observed in oprD
included small and large deletions, insertions and duplications
causing frame shifts in the oprD coding sequence as well as
substitutions resulting in early translational termination
(Table 2).
Characterization of oprD allelic diversity was performed
by comparing the observed mutations with those deposited
in the Pseudomonas Genome Database [13,14], which
showed that the isolates were broadly distributed among
three major OprD cluster groups (Group A-6 isolates,
Group B-11 isolates, Group C-10 isolates). In addition to the
identified mutations, 13 of the oprD sequences contained
silent nucleotide polymorphisms that had not previously
been described, and that are reported here as novel alleles
(Table 2). Half of those novel alleles belong to the OprD
cluster Group A. These findings suggest that the imipenem
resistance phenotypes observed can be attributed to inde-
pendent mutational events that led to the inactivation of
oprD.
Four imipenem-resistant isolates (TY5010, TY5017,
TY5018 and TY5041) had functional oprD genes based on
sequence analysis. This suggests that a resistance mechanism
other than MexT-mediated OprD down-regulation or defec-
tive OprD mutations were responsible for the imipenem
resistance observed in these strains. Additional analysis also
ruled out the presence of the blaKPC, blaGES and blaOXA-40
carbapenemase genes. Moreover, additional phenotypic anal-
ysis (Hodge Test) excluded other undetected carbapenemase
genes in these strains [15]. To assess whether the down-reg-
ulation of oprD or up-regulation of ampC could account for
imipenem resistance in these strains, quantitative RT-PCR
was employed to assess the level of oprD and ampC expres-
sion in each strain. Only TY5010 exhibited significant down-
regulation of oprD, which was approximately nine-fold lower
than expression levels in PA14 (Table 2). AmpC was not
induced in TY5041, but was highly induced in TY5017 and
TY5018 (ampC : proC ration of 2690 and 4340, respectively),
which could account for their increased imipenem resistance
levels. To assess whether AmpC contained a mutation in its
DNA sequence that subsequently led to increased expres-
sion levels, sequence analysis of AmpC was performed. Inter-
estingly both isolates (TY5017 and TY5018) contained the
recently described T105A mutation, which has been shown
to lead to an increased affinity for imipenem and as such is
classified as an extended-spectrum AmpC [16]. However,
some authors suggest that T105A is only a polymorphism,
therefore additional analysis will be required to clarify the
exact role of this polymorphism in those strains. [17]. In
addition, TY5017 also had a previously described R79Q
mutation in addition to T105A, which have previously been
TABLE 1. Probes and primers used in quantitative reverse
transcription–polymerase chain reaction analysis
Target
gene UPL probea Primersb
proC #20 (5¢-CCAGCCAG-3¢) 5¢-CTTCGAAGCACTGGTGGAG-3¢
5¢-TTATTGGCCAAGCTGTTCG-3¢
mexE #61 (5¢-CTGGGCAA-3¢) 5¢-CACCCTGATCAAGGACGAAG-3¢
5¢-CCAGGACCAGCACGAACT-3¢
oprD #132 (5¢-TGCTGCTC-3¢) 5¢-GGGTTCATCGAAGACAGCAG-3¢
5¢-GCCGTCACGGTTGAAATAGT-3¢
ampC #23 (5¢-GGGCTGGG-3¢) 5¢-CCATCGCGGTTACTACAAGG-3¢
5¢-GAGATCGGCCAGTCGTAGG-3¢
aProbes from Roche Universal ProbeLibrary (Roche Applied Biosystems, Bur-
gess Hill, UK) labelled at the 5¢-terminal with fluorescein (FAM) and 3¢-proximal
with a dark quencher dye.
bSpecific primers for probe hydrolysis reaction.
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reported to coincide [16]. Overall, the combined down-regu-
lation of oprD and the induction of ampC could account for
the imipenem phenotype observed.
A single imipenem-resistant isolate (TY5040) exhibited no
defective mutations in oprD, had levels of oprD expression
comparable to PA14 and did not over-express ampC. A
possible explanation could be the post-transcriptional down-
regulation of oprD, which has been previously suggested
[18]. Alternatively, an as yet uncharacterized resistance
mechanism could contribute to imipenem resistance in this
strain. However, the majority of imipenem-resistant clinical
strains show mutational inactivation of OprD as the pre-
dominant pathway leading to imipenem resistance in the iso-
lates obtained in the Zonguldak Karaelmas University
Hospital in Turkey.
Acknowledgements
We thank Pat Higgins for excellent technical assistance dur-
ing the course of this work. Fergal O’Gara has received
funding from the European Commission (MTKD-CT-2006-
042062; O36314), Science Foundation Ireland (SFI 04/BR/
B0597; 07/IN.1/B948; 08/RFP/GEN1295; 08/RFP/GEN1319;
09/RFP/BMT2350), the Department of Agriculture and Food
(DAF RSF 06 321; DAF RSF 06 377; FIRM 08/RDC/629),
the Irish Research Council for Science, Engineering and
Technology (05/EDIV/FP107), the Health Research Board
(RP/2006/271; RP/2007/290; HRA/2009/146), the Environ-
mental Protection Agency (EPA2006-PhD-S-21; EPA2008-
PhD-S-2), the Marine Institute (Beaufort award C2CRA
2007/082), the Higher Education Authority of Ireland
(PRTLI3) and the Health Service Executive (HSE) surveil-
lance fund. Marlies Mooij has received funding by FP7-PEO-
PLE-2009-RG, EU 256596, 2010-2013 and IRCSET EMBARK
PD/2011/2414.
Transparency Declaration
The authors declare no conflicts of interest.
References
1. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant
Pseudomonas aeruginosa: clinical impact and complex regulation of
chromosomally encoded resistance mechanisms. Clin Microbiol Rev
2009; 22: 582–610.
TABLE 2. Molecular investigation of chromosomal resistance mechanisms in imipenem-resistant Pseudomonas aeruginosa iso-
lates
Strain
Imipenem
MIC (lg/mL)
Resistance gene expressiona oprD gene sequence
mexE ampC oprD DOMb Non-synonymous/frame shift mutations
TY5003 16 1.33 NA NA yes large 427-bp deletion from NT 47
TY5005 16 0.39 NA NA yes 1-bp insertion after NT 1205 ﬁ Frame shift ﬁ stop codon at NT 1423-5
TY5007 32 2.98 NA NA yes large 427-bp deletion from NT 47
TY5009 16 0.45 NA NA yes C-T base substitution at NT 1279 ﬁ stop codon at NT 1279-81
TY5011 32 0.02 NA NA yes 11-bp deletion of NT96-106 ﬁ Frame shift ﬁ stop codon at NT 147-50
TY5014 16 0.95 NA NA yes 1-bp deletion of NT38 ﬁ Frame shift ﬁ stop codon at NT280-2
TY5021 16 14.17 NA NA yes G-T base substitution at NT 901 ﬁ early stop codon
TY5027 32 1.09 NA NA yes duplication of CT at NT 670-1 ﬁ Frame shift ﬁ stop codon at NT 688-90
TY5028 8 0.90 NA NA yes 1-bp deletion of NT 903 ﬁ Frame shift ﬁ stop codon at NT 1033-5
TY5030 16 0.54 NA NA yes 28-bp deletion from of NT 662-690 ﬁ Frame shift ﬁ stop codon at NT 760-2
TY5031 32 0.52 NA NA yes A-G base substitution at NT 1251 ﬁ early stop codon
TY5033 32 1.28 NA NA yes duplication of G at NT 455 ﬁ Frame shift ﬁ stop codon at NT 219-21
TY5034 16 0.30 NA NA yes 4-bp deletion of NT 869-872 ﬁ Frame shift ﬁ stop codon at NT 1030-2
TY5036 8 0.30 NA NA yes 1-bp deletion of NT 737 ﬁ Frame shift ﬁ stop codon at NT 1033-5
TY5040 32 1.24 NA NA yes C-A base substitution at NT 1197 ﬁ early stop codon
TY5043 >32 1.88 NA NA yes duplication of CCTC at NT 69-72 ﬁ Frame shift ﬁ stop codon at NT 691-693
TY5046 16 0.01 NA NA yes C-T base substitution at NT 703 ﬁ stop codon at NT 703-5
TY5053 32 0.02 NA NA yes duplication of G at NT 455 ﬁ Frame shift ﬁ stop codon at NT 219-21
TY5056 16 0.01 NA NA yes 13-bp deletion of NT 63-75 ﬁ Frame shift ﬁ stop codon at NT 1021-3
TY5062 16 0.11 NA NA yes large 427-bp deletion from NT 47
TY5066 16 0.78 NA NA yes duplication of G at NT 455 ﬁ Frame shift ﬁ stop codon at NT 219-21
TY5067 32 0.03 NA NA yes G-A base substitution NT 195 ﬁ early stop codon
TY5076 32 0.04 NA NA yes C-T base substitution NT 1295 ﬁ early stop codon
TY5010 32 0.55 0.34 0.11 no –
TY5017 >32 0.90 2690.16 0.53 no –
TY5018 16 0.38 4340.36 0.54 no C-G base substitution at NT 452 (Ala-Gly)
TY5041 >32 0.21 0.19 0.53 no –
aTarget gene : proC ratio in clinical isolates relative to PA14.
bNA, not applicable.
cDOM, defective OprD mutation. These oprD sequences are predicted to encode non-functional Opr porins.
E264 Clinical Microbiology and Infection, Volume 18 Number 7, July 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E262–E265
2. Gaynes R, Edwards JR. Overview of nosocomial infections caused by
gram-negative bacilli. Clin Infect Dis 2005; 41: 848–854.
3. El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas
aeruginosa pneumonia. J Antimicrob Chemother 2009; 64: 229–238.
4. American Thoacic Society; Infectious Disease Society of America.
Guidelines for the management of adults with hospital-acquired, ven-
tilator-associated, and healthcare-associated pneumonia. Am J Respir
Crit Care Med 2005; 171: 388–416.
5. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. Imipenem
resistance of Pseudomonas in pneumonia: a systematic literature
review. BMC Pulm Med 2010; 10: 45.
6. Onguru P, Erbay A, Bodur H et al. Imipenem-resistant Pseudomonas
aeruginosa: risk factors for nosocomial infections. J Korean Med Sci
2008; 23: 982–987.
7. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-
resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro
Surveill 2008; 13: 47.
8. Kulah C, Mooij MJ, Comert F et al. Characterisation of carbapenem-
resistant Acinetobacter baumannii outbreak strains producing OXA-58
in Turkey. Int J Antimicrob Agents 2010; 36: 114–118.
9. Martinez JL. Environmental pollution by antibiotics and by antibiotic
resistance determinants. Environ Pollut 2009; 157: 2893–2902.
10. Kohler T, Epp SF, Curty LK, Pechere JC. Characterization of MexT,
the regulator of the MexE-MexF-OprN multidrug efflux system of
Pseudomonas aeruginosa. J Bacteriol 1999; 181: 6300–6305.
11. Tian ZX, Mac Aogain M, O’Connor HF et al. MexT modulates viru-
lence determinants in Pseudomonas aeruginosa independent of the
MexEF-OprN efflux pump. Microb Pathog 2009; 47: 237–241.
12. Tian ZX, Fargier E, Mac Aogain M, Adams C, Wang YP, O’Gara F.
Transcriptome profiling defines a novel regulon modulated by the
LysR-type transcriptional regulator MexT in Pseudomonas aeruginosa.
Nucleic Acids Res 2009; 37: 7546–7559.
13. Pirnay JP, Bilocq F, Pot B et al. Pseudomonas aeruginosa population
structure revisited. PLoS ONE 2009; 4: e7740.
14. Winsor GL, Van Rossum T, Lo R et al. Pseudomonas Genome Data-
base: facilitating user-friendly, comprehensive comparisons of micro-
bial genomes. Nucleic Acids Res 2009; 37: D483–D488.
15. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified
Hodge and EDTA-disk synergy tests to screen metallo-beta-lactam-
ase-producing strains of Pseudomonas and Acinetobacter species. Clin
Microbiol Infect 2001; 7: 88–91.
16. Rodriguez-Martinez JM, Poirel L, Nordmann P. Extended-spectrum
cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Che-
mother 2009; 53: 1766–1771.
17. Zamorano L, Moya B, Juan C, Oliver A. Differential beta-lactam resis-
tance response driven by ampD or dacB (PBP4) inactivation in geneti-
cally diverse Pseudomonas aeruginosa strains. J Antimicrob Chemother
2010; 65: 1540–1542.
18. Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation
of the Pseudomonas aeruginosa outer membrane porin OprD selective
for imipenem and basic amino acids. Antimicrob Agents Chemother
1999; 43: 1085–1090.
CMI Research Note E265
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E262–E265
